Literature DB >> 34107339

Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review.

Hadir Shakshouk1, Eric R Tkaczyk2, Edward W Cowen3, Rokea A El-Azhary4, Shahrukh K Hashmi5, Saad J Kenderian6, Julia S Lehman7.   

Abstract

Chronic graft-versus-host disease (cGVHD), a potentially debilitating complication of hematopoietic cell transplantation, confers increased risk for mortality. Whereas treatment decisions rely on an accurate assessment of disease activity/severity, validated methods of assessing cutaneous cGVHD activity/severity appear to be limited. In this study, we aimed to identify and evaluate current data on the assessment of disease activity/severity in cutaneous cGVHD. Using modified PRISMA methods, we performed a critical literature review for relevant articles. Our literature search identified 1741 articles, of which 1635 were excluded as duplicates or failure to meet inclusion criteria. Of the included studies (n = 106), 39 (37%) addressed clinical and/or histopathologic parameters, 53 (50%) addressed serologic parameters, 8 (7.5%) addressed imaging parameters, and 6 (5.5%) addressed computer-based technologies. The only formally validated metric of disease activity/severity assessment in cutaneous cGVHD is the National Institutes of Health consensus scoring system, which is founded on clinical assessment alone. The lack of an objective marker for cGVHD necessitates further studies. An evaluation of the potential contributions of serologic, imaging, and/or computer-based technologies is warranted.
Copyright © 2021 The American Society for Transplantation and Cellular Therapy. All rights reserved.

Entities:  

Keywords:  Disease activity; GVHD; Graft-versus-host disease; Monitoring; Sclerotic GVHD; dermatology; skin; skin biopsy

Mesh:

Year:  2021        PMID: 34107339      PMCID: PMC8719782          DOI: 10.1016/j.jtct.2021.05.030

Source DB:  PubMed          Journal:  Transplant Cell Ther        ISSN: 2666-6367


  99 in total

1.  NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD.

Authors:  L M Curtis; L Grkovic; S A Mitchell; S M Steinberg; E W Cowen; M B Datiles; J Mays; C Bassim; G Joe; L E Comis; A Berger; D Avila; T Taylor; D Pulanic; K Cole; J Baruffaldi; D H Fowler; R E Gress; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2014-08-25       Impact factor: 5.483

2.  Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease.

Authors:  Hildegard T Greinix; David Pohlreich; Michal Kouba; Ulrike Körmöczi; Imke Lohmann; Karin Feldmann; Christoph Zielinski; Winfried F Pickl
Journal:  Biol Blood Marrow Transplant       Date:  2008-02       Impact factor: 5.742

3.  Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD.

Authors:  Joanne E Croudace; Charlotte F Inman; Ben E Abbotts; Sandeep Nagra; Jane Nunnick; Prem Mahendra; Charles Craddock; Ram Malladi; Paul A H Moss
Journal:  Blood       Date:  2012-09-25       Impact factor: 22.113

4.  Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.

Authors:  Joon Ho Moon; Sang Kyun Sohn; Anna Lambie; Laura Ellis; Nada Hamad; Jieun Uhm; Vikas Gupta; Jeffrey H Lipton; Hans A Messner; John Kuruvilla; Dennis Kim
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-18       Impact factor: 5.742

5.  Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.

Authors:  Erica Dander; Adriana Balduzzi; Greta Zappa; Giovanna Lucchini; Paolo Perseghin; Valentina Andrè; Elisabetta Todisco; Daoud Rahal; Maddalena Migliavacca; Daniela Longoni; Graziella Solinas; Antonello Villa; Emilio Berti; Pamela Della Mina; Matteo Parma; Paola Allavena; Ettore Biagi; Attilio Rovelli; Andrea Biondi; Giovanna D'Amico
Journal:  Transplantation       Date:  2009-12-15       Impact factor: 4.939

6.  Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients.

Authors:  Alessandro Racioppi; Tara Dalton; Sendhilnathan Ramalingam; Kristi Romero; Yi Ren; Lauren Bohannon; Consuelo Arellano; Jude Jonassaint; Hilary Miller; Ian Barak; Laura J Fish; Taewoong Choi; Cristina Gasparetto; Gwynn D Long; Richard D Lopez; David A Rizzieri; Stefanie Sarantopoulos; Mitchell E Horwitz; Nelson J Chao; Nirmish R Shah; Anthony D Sung
Journal:  Transplant Cell Ther       Date:  2020-12-13

7.  Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.

Authors:  Mohammad Abu Zaid; Juan Wu; Cindy Wu; Brent R Logan; Jeffrey Yu; Corey Cutler; Joseph H Antin; Sophie Paczesny; Sung Won Choi
Journal:  Blood       Date:  2016-11-08       Impact factor: 22.113

8.  Use of a durometer to assess skin hardness.

Authors:  V Falanga; B Bucalo
Journal:  J Am Acad Dermatol       Date:  1993-07       Impact factor: 11.527

9.  Nail dystrophy, edema, and eosinophilia: harbingers of severe chronic GVHD of the skin in children.

Authors:  J T Huang; C N Duncan; D Boyer; H Khosravi; L E Lehmann; A Saavedra
Journal:  Bone Marrow Transplant       Date:  2014-09-22       Impact factor: 5.483

10.  Dermoscopy of Cutaneous Graft-Versus-Host-Disease in Patients After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Grażyna Kaminska-Winciorek; Iris Zalaudek; Włodzimierz Mendrek; Magdalena Jaworska; Maksymilian Gajda; Jerzy Hołowiecki; Jan Szymszal; Sebastian Giebel
Journal:  Dermatol Ther (Heidelb)       Date:  2020-07-16
View more
  1 in total

Review 1.  Expanding Personalized, Data-Driven Dermatology: Leveraging Digital Health Technology and Machine Learning to Improve Patient Outcomes.

Authors:  Shannon Wongvibulsin; Tracy M Frech; Mary-Margaret Chren; Eric R Tkaczyk
Journal:  JID Innov       Date:  2022-02-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.